Cargando…
Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial
BACKGROUND: Early treatment of COVID-19 patients could reduce hospitalization and death. The effect of corticosteroids in the outpatient setting is still unknown. This study aimed to determine the effect of corticosteroids in the prevention of hospitalization of nonsevere cases. MATERIALS AND METHOD...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331530/ https://www.ncbi.nlm.nih.gov/pubmed/37434926 http://dx.doi.org/10.4103/abr.abr_72_22 |
_version_ | 1785070273302626304 |
---|---|
author | Amra, Babak Vaezi, Atefeh Soltaninejad, Forogh Salahi, Mehrdad Salmasi, Mehrzad Haghjooy Javanmard, Shaghayegh |
author_facet | Amra, Babak Vaezi, Atefeh Soltaninejad, Forogh Salahi, Mehrdad Salmasi, Mehrzad Haghjooy Javanmard, Shaghayegh |
author_sort | Amra, Babak |
collection | PubMed |
description | BACKGROUND: Early treatment of COVID-19 patients could reduce hospitalization and death. The effect of corticosteroids in the outpatient setting is still unknown. This study aimed to determine the effect of corticosteroids in the prevention of hospitalization of nonsevere cases. MATERIALS AND METHODS: This study is a multicenter randomized controlled trial. Seventy five nonsevere COVID-19 patients presented between days 7 and 14 of their symptoms received either prednisolone or placebo. The primary outcome was hospitalization. The study protocol was registered in the Iranian Registry of Clinical Trials on December 2, 2020 (IRCT20171219037964N2). RESULTS: Although the rate of hospitalization in the prednisolone group was higher than the placebo group (10.8% vs. 7.9%, respectively), it was not statistically significant (P value.,6). One patient in each group reported an adverse event and withdrew the medication. CONCLUSION: Considering the null effect of corticosteroids in the prevention of hospitalization in outpatient settings, it is suggested not to consider corticosteroids for outpatient treatment. |
format | Online Article Text |
id | pubmed-10331530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-103315302023-07-11 Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial Amra, Babak Vaezi, Atefeh Soltaninejad, Forogh Salahi, Mehrdad Salmasi, Mehrzad Haghjooy Javanmard, Shaghayegh Adv Biomed Res Original Article BACKGROUND: Early treatment of COVID-19 patients could reduce hospitalization and death. The effect of corticosteroids in the outpatient setting is still unknown. This study aimed to determine the effect of corticosteroids in the prevention of hospitalization of nonsevere cases. MATERIALS AND METHODS: This study is a multicenter randomized controlled trial. Seventy five nonsevere COVID-19 patients presented between days 7 and 14 of their symptoms received either prednisolone or placebo. The primary outcome was hospitalization. The study protocol was registered in the Iranian Registry of Clinical Trials on December 2, 2020 (IRCT20171219037964N2). RESULTS: Although the rate of hospitalization in the prednisolone group was higher than the placebo group (10.8% vs. 7.9%, respectively), it was not statistically significant (P value.,6). One patient in each group reported an adverse event and withdrew the medication. CONCLUSION: Considering the null effect of corticosteroids in the prevention of hospitalization in outpatient settings, it is suggested not to consider corticosteroids for outpatient treatment. Wolters Kluwer - Medknow 2023-05-15 /pmc/articles/PMC10331530/ /pubmed/37434926 http://dx.doi.org/10.4103/abr.abr_72_22 Text en Copyright: © 2023 Advanced Biomedical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Amra, Babak Vaezi, Atefeh Soltaninejad, Forogh Salahi, Mehrdad Salmasi, Mehrzad Haghjooy Javanmard, Shaghayegh Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial |
title | Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial |
title_full | Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial |
title_fullStr | Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial |
title_full_unstemmed | Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial |
title_short | Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial |
title_sort | steroid in the treatment of outpatient covid-19: a multicenter randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331530/ https://www.ncbi.nlm.nih.gov/pubmed/37434926 http://dx.doi.org/10.4103/abr.abr_72_22 |
work_keys_str_mv | AT amrababak steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial AT vaeziatefeh steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial AT soltaninejadforogh steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial AT salahimehrdad steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial AT salmasimehrzad steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial AT haghjooyjavanmardshaghayegh steroidinthetreatmentofoutpatientcovid19amulticenterrandomizedcontrolledtrial |